| Dr Sanford D Zelnick, DO | |
|
415 E Noble Ave, Bushnell, FL 33513-5603 | |
| (352) 569-3100 | |
| (352) 793-6067 |
| Full Name | Dr Sanford D Zelnick |
|---|---|
| Gender | Male |
| Speciality | Preventive Medicine |
| Experience | 47 Years |
| Location | 415 E Noble Ave, Bushnell, Florida |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1750363529 | NPI | - | NPPES |
| 92318 | Other | COMMERCIAL | |
| 265470900 | Medicaid | FL |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Florida Department Of Health | 3072424282 | 111 |
News Archive
Savient Pharmaceuticals, Inc. today announced the closing of its sale of $230 million aggregate principal amount of 4.75% Convertible Senior Notes due 2018 (the "Notes"). The aggregate principal amount of Notes sold reflects the full exercise by the underwriters of their option to purchase $30 million principal amount of Notes to cover over-allotments.
Hokkaido University researchers have discovered that a nonsteroid anti-inflammatory drug used for treating colds suppresses the spread of bladder cancers and reduces their chemoresistance in mice, raising hopes of a future cure for advanced bladder cancers.
Sunlight Research – The Source for Patent Analysis, today announced the release of its comprehensive Stem Cell Industry Report analyzing the U.S. Stem Cell patent landscape. Stem cells are particularly attractive for use as cellular therapies because they self-renew and have the capacity to produce many different specialized cell types.
A survey of physicians by Majestic Research found that Boston Scientific's March 15 decision to withdraw from the ICD market will have a meaningful long-term impact. Among surveyed electrophysiologists, 56% report the recent announcements and actions have negatively impacted their perceptions of the overall quality of Boston Scientific's ICD devices and 52% said that they would be less likely to use the company's devices in the future.
› Verified 1 days ago
| Entity Name | Florida Department Of Health |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184688947 PECOS PAC ID: 3072424282 Enrollment ID: O20031126000379 |
News Archive
Savient Pharmaceuticals, Inc. today announced the closing of its sale of $230 million aggregate principal amount of 4.75% Convertible Senior Notes due 2018 (the "Notes"). The aggregate principal amount of Notes sold reflects the full exercise by the underwriters of their option to purchase $30 million principal amount of Notes to cover over-allotments.
Hokkaido University researchers have discovered that a nonsteroid anti-inflammatory drug used for treating colds suppresses the spread of bladder cancers and reduces their chemoresistance in mice, raising hopes of a future cure for advanced bladder cancers.
Sunlight Research – The Source for Patent Analysis, today announced the release of its comprehensive Stem Cell Industry Report analyzing the U.S. Stem Cell patent landscape. Stem cells are particularly attractive for use as cellular therapies because they self-renew and have the capacity to produce many different specialized cell types.
A survey of physicians by Majestic Research found that Boston Scientific's March 15 decision to withdraw from the ICD market will have a meaningful long-term impact. Among surveyed electrophysiologists, 56% report the recent announcements and actions have negatively impacted their perceptions of the overall quality of Boston Scientific's ICD devices and 52% said that they would be less likely to use the company's devices in the future.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Sanford D Zelnick, DO 415 E Noble Ave, Bushnell, FL 33513-5603 Ph: (352) 569-3100 | Dr Sanford D Zelnick, DO 415 E Noble Ave, Bushnell, FL 33513-5603 Ph: (352) 569-3100 |
News Archive
Savient Pharmaceuticals, Inc. today announced the closing of its sale of $230 million aggregate principal amount of 4.75% Convertible Senior Notes due 2018 (the "Notes"). The aggregate principal amount of Notes sold reflects the full exercise by the underwriters of their option to purchase $30 million principal amount of Notes to cover over-allotments.
Hokkaido University researchers have discovered that a nonsteroid anti-inflammatory drug used for treating colds suppresses the spread of bladder cancers and reduces their chemoresistance in mice, raising hopes of a future cure for advanced bladder cancers.
Sunlight Research – The Source for Patent Analysis, today announced the release of its comprehensive Stem Cell Industry Report analyzing the U.S. Stem Cell patent landscape. Stem cells are particularly attractive for use as cellular therapies because they self-renew and have the capacity to produce many different specialized cell types.
A survey of physicians by Majestic Research found that Boston Scientific's March 15 decision to withdraw from the ICD market will have a meaningful long-term impact. Among surveyed electrophysiologists, 56% report the recent announcements and actions have negatively impacted their perceptions of the overall quality of Boston Scientific's ICD devices and 52% said that they would be less likely to use the company's devices in the future.
› Verified 1 days ago